Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

bioAffinity Technologies, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES CLOSES PRIVATE PLACEMENT AND WARRANT INDUCEMENT TRANSACTION FOR APPROXIMATELY $1.2 MILLION IN GROSS PROCEEDS.

BIOAFFINITY TECHNOLOGIES ANNOUNCES CLOSING OF PRIVATE PLACEMENT AND WARRANT INDUCEMENT TRANSACTION FOR APPROXIMATELY $1.2 MILLION IN GROSS PROCEEDS

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES REPORTS Q2 2025 RESULTS; CYPATH LUNG REVENUES UP 62% YEAR-OVER-YEAR IN FIRST SIX MONTHS OF 2025.

BIOAFFINITY TECHNOLOGIES REPORTS SECOND QUARTER 2025 RESULTS

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES ANNOUNCES PRICING OF PRIVATE PLACEMENT AND WARRANT INDUCEMENT TRANSACTION.

BIOAFFINITY TECHNOLOGIES ANNOUNCES PRICING OF PRIVATE PLACEMENT AND WARRANT INDUCEMENT TRANSACTION FOR APPROXIMATELY $1.2 MILLION IN GROSS PROCEEDS

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES REPORTS A SIGNIFICANT SURGE IN COMMERCIAL SALES OF CYPATH LUNG WITH BACK-TO-BACK RECORD MONTHLY SALES IN JUNE AND JULY.

BIOAFFINITY TECHNOLOGIES REPORTS ACCELERATING GROWTH IN CYPATH LUNG TEST SALES

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CYPATH LUNG DETECTS A RARE MUCINOUS ADENOCARCINOMA AT STAGE 1A IN A HIGH-RISK INDIVIDUAL WHOSE PREVIOUS TESTS SUGGESTED A LOW PROBABILITY OF CANCER.

CASE STUDY: CYPATH LUNG DETECTS STAGE 1A LUNG CANCER IN HIGH-RISK PATIENT WITH INCONCLUSIVE IMAGING AND LOW-RISK SERUM TEST RESULTS

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--CANADA GRANTS BIOAFFINITY TECHNOLOGIES NEW PATENT THAT PROTECTS ITS PROPRIETARY TECHNOLOGY THAT POWERS ITS FLAGSHIP PRODUCT, CYPATH LUNG.

CANADA AWARDS NEW PATENT TO BIOAFFINITY TECHNOLOGIES FOR CYPATH LUNG, COMPANY'S NONINVASIVE LUNG CANCER DIAGNOSTIC

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES HAS RECEIVED NOTIFICATION OF ALLOWANCE FROM CHINA FOR A PATENT ON ITS TECHNOLOGY FOR PREDICTING THE LIKELIHOOD OF LUNG CANCER.

BIOAFFINITY TECHNOLOGIES ANNOUNCES NOTIFICATION OF CHINA PATENT AWARD FOR COMPANY'S NONINVASIVE LUNG CANCER DIAGNOSTIC

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY SCIENTISTS PRESENT BREAKTHROUGH RESEARCH ON USING SIRNAS TO KNOCK DOWN TWO RECEPTORS ON THE CELL MEMBRANE TO SELECTIVELY KILL CANCER CELLS.

BIOAFFINITY TECHNOLOGIES SCIENTISTS PRESENT BREAKTHROUGH CANCER RESEARCH AT RNA THERAPEUTICS CONFERENCE

SAN ANTONIO--(BUSINESS WIRE)-- #ALA--BIOAFFINITY CEO MARIA ZANNES JOINS THE AMERICAN LUNG ASSOCIATION IN TEXAS' LEADERSHIP BOARD OF TO ADVANCE PREVENTION AND TREATMENT OF LUNG DISEASE.

BIOAFFINITY TECHNOLOGIES PRESIDENT AND CEO MARIA ZANNES APPOINTED TO AMERICAN LUNG ASSOCIATION IN TEXAS' LEADERSHIP BOARD

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES ANNOUNCES NEW PATENT FOR METHOD OF SELECTIVELY KILLING CANCER BY TARGETING TWO SPECIFIC RECEPTORS ON THE CELL MEMBRANE.

BIOAFFINITY TECHNOLOGIES ANNOUNCES NEW U.S. PATENT FOR NOVEL BROAD SPECTRUM CANCER THERAPEUTICS

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES REPORTS FIRST-QUARTER 2025 RESULTS.

BIOAFFINITY TECHNOLOGIES REPORTS FIRST QUARTER 2025 RESULTS

JERSEY CITY, N.J. , MAY 7, 2025 /PRNEWSWIRE/ -- WALLACHBETH CAPITAL LLC, A LEADING PROVIDER OF CAPITAL MARKETS AND INSTITUTIONAL EXECUTION SERVICES, ANNOUNCED TODAY THAT BIOAFFINITY TECHNOLOGIES, INC. (NASDAQ: BIAF, BIAFW)A BIOTECHNOLOGY COMPANY FOCUSED ON THE NEED FOR NONINVASIVE TESTS FOR THE DETECTION OF EARLY-STAGE CANCER, HAS CLOSED ITS PREVIOUSLY ANNOUNCED BEST EFFORTS OFFERING OF SECURITIES AS DESCRIBED BELOW FOR AGGREGATE GROSS PROCEEDS TO THE COMPANY OF $3.25 MILLION, BEFORE DEDUCTING AGENT FEES AND OTHER ESTIMATED EXPENSES PAYABLE BY THE COMPANY.

WALLACHBETH CAPITAL ANNOUNCES CLOSING OF BIOAFFINITY TECHNOLOGIES $3.25M OFFERING

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES TODAY CLOSED THE PREVIOUSLY ANNOUNCED BEST EFFORTS OFFERING OF SECURITIES FOR AGGREGATE GROSS PROCEEDS OF $3.25 MILLION.

BIOAFFINITY TECHNOLOGIES ANNOUNCES CLOSING OF $3.25 MILLION OFFERING

SAN ANTONIO--(BUSINESS WIRE)-- #BIAF--BIOAFFINITY TECHNOLOGIES ANNOUNCES THE PRICING OF A BEST EFFORTS OFFERING OF SECURITIES FOR AGGREGATE GROSS PROCEEDS OF $3.25 MILLION.

bioAffinity Technologies, Inc.

BIAF

Price

Financials Overview

Financial Reports

No items found.

Press Releases

bioAffinity Technologies, Inc.

BIAF.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BIAF